

Tatsuya Yamashita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4120750/publications.pdf>

Version: 2024-02-01

110
papers

2,644
citations

236612

25
h-index

233125

45
g-index

117
all docs

117
docs citations

117
times ranked

3454
citing authors

#	ARTICLE	IF	CITATIONS
1	BMP9-ID1 Signaling Activates HIF-1 α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1475.	1.8	14
2	The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2022, 12, 987.	1.6	3
3	Comparative analysis of medical costs after hepatectomy versus radiofrequency ablation in patients with hepatocellular carcinoma in real-world clinical practice. <i>Hepatology Research</i> , 2022, , .	1.8	1
4	Oral Corticosteroids Impair Mucin Production and Alter the Posttransplantation Microbiota in the Gut. <i>Digestion</i> , 2022, 103, 269-286.	1.2	1
5	Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2801.	1.8	13
6	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. <i>Nature Communications</i> , 2022, 13, .	5.8	8
7	A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4095-4095.	0.8	1
8	Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 190-200.	1.8	9
9	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
10	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. <i>Cytotherapy</i> , 2021, 23, 137-145.	0.3	10
11	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	2.9	39
12	CX3CL1-CX3CR1 Signaling Deficiency Exacerbates Obesity-induced Inflammation and Insulin Resistance in Male Mice. <i>Endocrinology</i> , 2021, 162, .	1.4	16
13	The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients. <i>Hepatology International</i> , 2021, 15, 695-706.	1.9	7
14	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021, 10, 275-284.	4.2	29
15	Serum Laminin β 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 760-775.	3.6	21
16	REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4162-TPS4162.	0.8	2
17	BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2021, 15, 2203-2218.	2.1	14
18	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α -fetoprotein: Outcomes by treatment-emergent ascites. <i>Hepatology Research</i> , 2021, 51, 715-721.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. <i>Hepatology Research</i> , 2021, 51, 890-901.	1.8	5
20	Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2021, 11, 12885.	1.6	1
21	Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. <i>Stem Cell Research</i> , 2021, 54, 102425.	0.3	6
22	A case of traumatic diaphragmatic hernia that caused obstruction of middle hepatic vein. <i>Acta Hepatologica Japonica</i> , 2021, 62, 413-419.	0.0	0
23	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	3.7	58
24	Treatment patterns and medical costs after hepatectomy in real-world practice for patients with hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2021, 51, 1073-1081.	1.8	1
25	Chronic liver disease enables gut <i>Enterococcus faecalis</i> colonization to promote liver carcinogenesis. <i>Nature Cancer</i> , 2021, 2, 1039-1054.	5.7	26
26	Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. <i>Regenerative Therapy</i> , 2021, 18, 97-101.	1.4	12
27	C C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. <i>Metabolism: Clinical and Experimental</i> , 2021, 125, 154914.	1.5	33
28	Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. <i>American Journal of Cancer Research</i> , 2021, 11, 3163-3175.	1.4	4
29	Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. <i>Regenerative Therapy</i> , 2021, 18, 497-507.	1.4	2
30	REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. <i>Journal of Gastroenterology</i> , 2020, 55, 113-122.	2.3	123
31	Liver Resection for Multiple Hepatocellular Carcinomas. <i>Annals of Surgery</i> , 2020, 272, 145-154.	2.1	61
32	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 583-595.	4.2	71
33	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver. <i>Liver Cancer</i> , 2020, 9, 261-274.	4.2	5
34	Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. , 2020, 8, e001367.		62
35	Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 4607.	1.3	1
36	Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis. <i>Life</i> , 2020, 10, 177.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. <i>Translational Oncology</i> , 2020, 13, 100777.	1.7	17
38	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. <i>Cancer Medicine</i> , 2020, 9, 4907-4917.	1.3	2
39	IL28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1813-1820.	1.4	2
40	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 269-285.	2.3	14
41	A novel α -fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 4021.	1.6	6
42	Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. <i>Journal of Gastroenterology</i> , 2020, 55, 701-711.	2.3	16
43	Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 935-939.	0.4	7
44	Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. <i>Journal of Gastroenterology</i> , 2020, 55, 627-639.	2.3	23
45	Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. <i>Scientific Reports</i> , 2020, 10, 815.	1.6	41
46	Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Diabetes Therapy</i> , 2020, 11, 549-560.	1.2	7
47	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. <i>PLoS ONE</i> , 2020, 15, e0232089.	1.1	7
48	Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 871-884.	1.8	35
49	Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites. <i>Journal of Clinical Oncology</i> , 2020, 38, 4644-4644.	0.8	1
50	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup. <i>Journal of Clinical Oncology</i> , 2020, 38, 526-526.	0.8	5
51	Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial. <i>JMIR Research Protocols</i> , 2020, 9, e17904.	0.5	6
52	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
53	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
54	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0

#	ARTICLE	IF	CITATIONS
55	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
56	Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Liver Cancer, 2019, 8, 130-139.	4.2	21
57	Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. Hepatology, 2019, 69, 653-665.	3.6	56
58	Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clinical Journal of Gastroenterology, 2019, 12, 63-70.	0.4	4
59	Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. Journal of Gastroenterology, 2019, 54, 549-557.	2.3	26
60	Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatology Research, 2019, 49, 981-989.	1.8	27
61	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Medical Oncology, 2019, 36, 52.	1.2	9
62	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer, 2019, 8, 403-411.	4.2	28
63	Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Cancer Science, 2019, 110, 903-912.	1.7	11
64	Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1432-1440.	1.4	18
65	Development of novel diagnostic system for pancreatic cancer, including early stages, measuring <scp>mRNA</scp> of whole blood cells. Cancer Science, 2019, 110, 1364-1388.	1.7	17
66	Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1829-1835.	1.4	18
67	Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 2701-2711.	2.3	25
68	Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection. Hepatology, 2019, 70, 25-39.	3.6	26
69	MicroRNA-10a Impairs Liver Metabolism in Hepatitis C Virus-Related Cirrhosis Through Deregulation of the Circadian Clock Gene Brain and Muscle Aryl Hydrocarbon Receptor Nuclear Translocator-Like 1. Hepatology Communications, 2019, 3, 1687-1703.	2.0	14
70	Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biology, 2019, 20, 252.	3.8	78
71	Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. BMC Gastroenterology, 2019, 19, 217.	0.8	15
72	Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. International Journal of Radiation Biology, 2019, 95, 571-579.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).. Journal of Clinical Oncology, 2019, 37, 320-320.	0.8	8
74	Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.. Journal of Clinical Oncology, 2019, 37, 323-323.	0.8	3
75	Dynamical changes of treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice.. Journal of Clinical Oncology, 2019, 37, 407-407.	0.8	2
76	Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.. Journal of Clinical Oncology, 2019, 37, 355-355.	0.8	1
77	Immune response to human telomerase reverse transcriptase-derived helper T cell epitopes in hepatocellular carcinoma patients. Liver International, 2018, 38, 1635-1645.	1.9	7
78	Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of β -catenin and hepatocyte nuclear factor χ in hepatocellular carcinoma. Hepatology Research, 2018, 48, 205-216.	1.8	28
79	Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. Journal of Gastroenterology, 2018, 53, 740-751.	2.3	17
80	Current positioning of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Annals of Oncology, 2018, 29, vii10.	0.6	0
81	Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Japanese Journal of Clinical Oncology, 2018, 48, 966-973.	0.6	16
82	Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients. Liver International, 2018, 38, 2040-2050.	1.9	13
83	Distinct notch signaling expression patterns between nucleoside and nucleotide analogues treatment for hepatitis B virus infection. Biochemical and Biophysical Research Communications, 2018, 501, 682-687.	1.0	1
84	Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatology Research, 2018, 48, 956-966.	1.8	39
85	Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides. PLoS ONE, 2018, 13, e0198264.	1.1	9
86	Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS ONE, 2018, 13, e0191026.	1.1	32
87	Surrogacy of time to prgression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, 403-403.	0.8	0
88	Association Between High-Avidity T-Cell Receptors, Induced by α -Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. Gastroenterology, 2017, 152, 1395-1406.e10.	0.6	61
89	Lidocaine spray alone is similar to spray plus viscous solution for pharyngeal observation during transoral endoscopy: a clinical randomized trial. Endoscopy International Open, 2017, 05, E47-E53.	0.9	11
90	Treatment Outcome and Prognosis of Portal Vein Thrombosis. Gastroenterology, 2017, 152, S1146.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 236-249.	4.2	24
92	Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0188549.	1.1	27
93	Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. <i>BMC Cancer</i> , 2017, 17, 870.	1.1	25
94	Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170291.	1.1	13
95	A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2017, 37, 3397-3403.	0.5	12
96	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 338.	1.1	12
97	Postâ€­progression survival and progressionâ€­free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. <i>Hepatology Research</i> , 2016, 46, 650-656.	1.8	66
98	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Childâ€­Pugh B cirrhosis. <i>Cancer Science</i> , 2016, 107, 1263-1269.	1.7	22
99	Argon plasma coagulation therapy after submucosal injection of a normal saline solution for local recurrence of large nonampullary duodenal neoplasm. <i>VideoGIE</i> , 2016, 1, 55-56.	0.3	0
100	Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 715-725.	2.0	58
101	Response to Importance of confounding factors in assessing fatty acid compositions in patients with nonâ€­alcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 1773-1773.	1.9	7
102	Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 364, 98-105.	3.2	31
103	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Hepatology Research</i> , 2015, 45, 949-959.	1.8	40
104	Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 369, 242-249.	3.2	37
105	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
106	Severe Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Deceased-donor and Living-donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3523-3535.	0.3	25
107	Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. <i>Hepatology</i> , 2014, 60, 1674-1685.	3.6	104
108	Treatment strategies for hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2013, 43, 44-50.	1.8	19

#	ARTICLE	IF	CITATIONS
109	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012, 32, 15-23.	1.1	9
110	Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 281-290.	0.9	64